719 related articles for article (PubMed ID: 22734512)
21. Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder.
Yamaguchi O; Marui E; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Ikeda Y; Ohkawa S
BJU Int; 2014 Jun; 113(6):951-60. PubMed ID: 24471907
[TBL] [Abstract][Full Text] [Related]
22. Combined treatment with a β
Imamura T; Ogawa T; Minagawa T; Nagai T; Suzuki T; Saito T; Yokoyama H; Nakazawa M; Ishizuka O
Neurourol Urodyn; 2017 Apr; 36(4):1026-1033. PubMed ID: 27367573
[TBL] [Abstract][Full Text] [Related]
23. Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction.
Nitti VW; Rosenberg S; Mitcheson DH; He W; Fakhoury A; Martin NE
J Urol; 2013 Oct; 190(4):1320-7. PubMed ID: 23727415
[TBL] [Abstract][Full Text] [Related]
24. Changes in urodynamic parameters after tolterodine treatment for female overactive bladder syndrome with or without voiding dysfunction.
Wu WY; Hsiao SM; Chang TC; Lin HH
J Obstet Gynaecol Res; 2011 May; 37(5):436-41. PubMed ID: 21272154
[TBL] [Abstract][Full Text] [Related]
25. Possible Involvement of Muscarinic Receptor Blockade in Mirabegron Therapy for Patients with Overactive Bladder.
Yamada S; Chimoto J; Shiho M; Okura T; Morikawa K; Wakuda H; Shinozuka K
J Pharmacol Exp Ther; 2021 May; 377(2):201-206. PubMed ID: 33658313
[TBL] [Abstract][Full Text] [Related]
26. Spinal effects of the fesoterodine metabolite 5-hydroxymethyl tolterodine and/or doxazosin in rats with or without partial urethral obstruction.
Füllhase C; Soler R; Gratzke C; Brodsky M; Christ GJ; Andersson KE
J Urol; 2010 Aug; 184(2):783-9. PubMed ID: 20639056
[TBL] [Abstract][Full Text] [Related]
27. Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats.
Yokoyama O; Yusup A; Miwa Y; Oyama N; Aoki Y; Akino H
J Urol; 2005 Nov; 174(5):2032-6. PubMed ID: 16217388
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats.
Hatanaka T; Ukai M; Watanabe M; Someya A; Ohtake A; Suzuki M; Ueshima K; Sato S; Sasamata M
Naunyn Schmiedebergs Arch Pharmacol; 2013 Mar; 386(3):247-53. PubMed ID: 23239087
[TBL] [Abstract][Full Text] [Related]
29. [Efficiency of tolterodine in the treatment of patients with overactive bladder].
Saiapova DR; Sitdykova MÈ
Urologiia; 2013; (6):32, 34-5. PubMed ID: 24649761
[TBL] [Abstract][Full Text] [Related]
30. Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity.
Kim Y; Yoshimura N; Masuda H; De Miguel F; Chancellor MB
BJU Int; 2006 Feb; 97(2):400-3. PubMed ID: 16430654
[TBL] [Abstract][Full Text] [Related]
31. Alpha1-adrenoceptor antagonists improve bladder storage function through reduction of afferent activity in rats with bladder outlet obstruction.
Yazaki J; Aikawa K; Shishido K; Yanagida T; Nomiya M; Ishibashi K; Haga N; Yamaguchi O
Neurourol Urodyn; 2011 Mar; 30(3):461-7. PubMed ID: 20886573
[TBL] [Abstract][Full Text] [Related]
32. Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom.
Aballéa S; Maman K; Thokagevistk K; Nazir J; Odeyemi IA; Hakimi Z; Garnham A; Toumi M
Clin Drug Investig; 2015 Feb; 35(2):83-93. PubMed ID: 25491433
[TBL] [Abstract][Full Text] [Related]
33. Effects of vibegron, a novel β
Maruyama I; Yamamoto S; Tsuchioka K; Yamazaki T
Eur J Pharmacol; 2020 Jul; 878():173096. PubMed ID: 32259514
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological and genetic analysis of mechanisms underlying detrusor overactivity in rats.
Yokoyama O
Neurourol Urodyn; 2010; 29(1):107-11. PubMed ID: 20025014
[TBL] [Abstract][Full Text] [Related]
35. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.
Oki T; Maruyama S; Takagi Y; Yamamura HI; Yamada S
Eur J Pharmacol; 2006 Jan; 529(1-3):157-63. PubMed ID: 16316647
[TBL] [Abstract][Full Text] [Related]
36. Preparation, characterization and pharmacological evaluation of tolterodine hydrogels for the treatment of overactive bladder.
Sun F; Sui C; Zhou Y; Liu X; Shi Y; Wu Y; Li Y
Int J Pharm; 2013 Sep; 454(1):532-8. PubMed ID: 23891744
[TBL] [Abstract][Full Text] [Related]
37. Prostaglandin E2 excitatory effects on rat urinary bladder: a comparison between the β-adrenoceptor modulation of non-voiding activity in vivo and micro-contractile activity in vitro.
Granato C; Korstanje C; Guilloteau V; Rouget C; Palea S; Gillespie JI
Naunyn Schmiedebergs Arch Pharmacol; 2015 Jul; 388(7):727-35. PubMed ID: 26063630
[TBL] [Abstract][Full Text] [Related]
38. Mirabegron: β3-adrenergic receptor agonist for the treatment of overactive bladder.
Bridgeman MB; Friia NJ; Taft C; Shah M
Ann Pharmacother; 2013; 47(7-8):1029-38. PubMed ID: 23757386
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic drug interaction study between overactive bladder drugs mirabegron and tolterodine in Japanese healthy postmenopausal females.
Nomura Y; Iitsuka H; Toyoshima J; Kuroishi K; Hatta T; Kaibara A; Katashima M; Moy S; Sawamoto T
Drug Metab Pharmacokinet; 2016 Dec; 31(6):411-416. PubMed ID: 27829538
[TBL] [Abstract][Full Text] [Related]
40. Long-term treatment with the beta-3 adrenoceptor agonist, mirabegron ameliorates detrusor overactivity and restores cyclic adenosine monophosphate (cAMP) levels in obese mice.
Calmasini FB; de Oliveira MG; Alexandre EC; da Silva FH; da Silva CPV; Candido TZ; Antunes E; Mónica FZ
Neurourol Urodyn; 2017 Aug; 36(6):1511-1518. PubMed ID: 27794199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
